Eli Lilly has reported fresh 48-week trial results on a combination of tirzepatide and eloralintide, and the numbers are hard to ignore: patients on the two-drug regimen lost up to 23.3% of their weight, well above the 14.8% seen with tirzepatide alone. The company’s study also found that the combination was stopped by as many as 27% of participants, a sharp reminder that more weight loss can come with a cost.
That is why the results are drawing attention now. Tirzepatide is the active ingredient in Zepbound, and Eli Lilly is trying to extend its lead in the GLP-1 space with newer treatments that can deliver still greater results. Eloralintide is an experimental drug that targets amylin, a natural hormone, rather than GLP-1, and the latest data are being watched as a test of whether Lilly can move beyond one successful therapy and build another.
The math shows why the combination stands out. A 23.3% loss is 8.5 percentage points better than tirzepatide alone, which works out to about 58% more weight loss relative to the 14.8% result. Compared with eloralintide by itself, the combination delivered 11 percentage points more, nearly doubling the 12.3% loss seen with the standalone drug. For a company valued at more than $1 trillion and trading at close to 40 times trailing earnings, results like these matter because they speak directly to whether Lilly can keep winning in obesity treatment.
But the same data that make the combination look promising also expose its weak point. A 27% discontinuation rate means more than one in four patients stopped treatment, and the company said many of those patients did so because of side effects. That is the part Lilly has to solve if it wants the regimen to move from an impressive trial result to something doctors and patients would actually stay on. Ken Custer pointed to earlier tirzepatide experience, saying high discontinuation rates were not unusual in a mid-stage trial several years ago, which gives Lilly a reason to believe the early rough edges may not be the final word.
The next question is not whether the combination can produce strong weight loss. It already has. The question is whether Lilly can lower the drop-off enough to make retatrutide-style ambitions in obesity medicine durable in practice, or whether the side effects will keep the treatment in the category of promising but hard to live with.
